Form 4: Brainstorm Cell Therapeutics Director Naor Nir Reports Changes in Beneficial Ownership

Director Naor Nir reports acquisition and disposal of Brainstorm Cell Therapeutics stock, including restricted stock units and adjustments for a reverse stock split.

Summary

• On January 1, 2025, Director Naor Nir reported changes in beneficial ownership of Brainstorm Cell Therapeutics Inc. stock.
• Nir acquired 30,666 shares of common stock through restricted stock units (RSUs) awarded under the 2014 Stock Incentive Plan at a price of $0.00.
• 50% of the RSUs vested on the grant date, and the remaining 50% will vest six months later, contingent upon continued employment.
• The report also reflects a 1-for-15 reverse stock split that took effect on October 1, 2024.
• Following these transactions, Nir beneficially owns 31,465 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock transactions by a company director. The RSU grant suggests a positive outlook from the director, but it's not overwhelmingly positive.

Positives

• The acquisition of shares through RSUs indicates confidence in the company's future by a director.

Future Outlook

The remaining 50% of the awarded RSUs will vest six months from the grant date, contingent on continued employment.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be indicative of their confidence in the company's prospects.

Stakeholder Impact

• The transactions reported may influence investor perception of the company's stock.

Key Dates

Keywords

Brainstorm Cell Therapeutics, BCLI, Form 4, Beneficial Ownership, Naor Nir, Restricted Stock Units, Reverse Stock Split, Director